To describe the clinical burden of metabolic dysfunction-associated steatohepatitis (MASH) in a large US cohort by assessing comorbidities, mortality, and the utility of non-invasive tests (NITs).
Key Findings:
MASH patients exhibit a high prevalence of comorbidities, including cardiovascular disease, obesity, and diabetes.
Non-CV comorbidities such as cancer and psychiatric disorders are under-researched in MASH populations, highlighting a critical gap in understanding their impact.
Mortality rates for overall, cardiovascular, and liver-related causes are significantly elevated in MASH patients, particularly those with advanced fibrosis.
Interpretation:
The study highlights the extensive clinical burden of MASH, emphasizing the need for comprehensive risk assessment and management strategies that include both CV and non-CV comorbidities.
Limitations:
The retrospective design may introduce biases and limit causal inferences, potentially affecting the reliability of the findings.
Reliance on claims data may result in underreporting of certain comorbidities and complications, which could skew the prevalence rates.
The study population may not fully represent all MASH patients due to exclusion criteria, limiting the generalizability of the results.
Conclusion:
This study underscores the importance of recognizing the multifaceted clinical burden of MASH and the potential role of non-invasive tests in patient management, which could inform future clinical guidelines.
